Back

argenx SE

Below you will find information from the register publication of inside information. The information has been provided by the organisation.

  • Registration date 06 sep 2018 - 07:00
  • Statutory name argenx SE
  • Title argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis

Related downloads

201809060000000002_argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis.docx

Date last update: 16 November 2018

Share information

Share on: Share this